Current Hematologic Malignancy Reports

Papers
(The TQCC of Current Hematologic Malignancy Reports is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
Circulating Tumor DNA in Lymphoma73
Advances in Risk Stratification and Treatment of Polycythemia Vera and Essential Thrombocythemia38
Therapy Resistance and Disease Progression in CML: Mechanistic Links and Therapeutic Strategies36
Future Directions in Chronic Phase CML Treatment35
MRD in Philadelphia Chromosome-Positive ALL: Methodologies and Clinical Implications26
IDH Inhibitors in AML—Promise and Pitfalls22
Monoclonal Gammopathy-Associated Neuropathy20
Sporadic and Familial Acute Myeloid Leukemia with CEBPA Mutations19
Novel Approaches to Managing Patients with Relapsed and Refractory Waldenström Macroglobulinemia18
Amyloidosis with Cardiac Involvement: Identification, Characterization, and Management16
Goal of a “Good Death” in End-of-Life Care for Patients with Hematologic Malignancies—Are We Close?16
JAK Inhibitors for Myelofibrosis: Strengths and Limitations16
Role of Germline Predisposition to Therapy-Related Myeloid Neoplasms15
A Journey Through JAK Inhibitors for the Treatment of Myeloproliferative Diseases12
A Pragmatic Approach to Managing Long-Term Adverse Effects in Chronic Myeloid Leukemia Treatment12
Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia: Strategies to Optimize Success and New Directions12
Financial Toxicity in Patients with Hematologic Malignancies: a Review and Need for Interventions12
Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)11
Balancing Quality, Cost, and Access During Delivery of Newer Cellular and Immunotherapy Treatments11
Health-Related Quality of Life of Patients with Chronic Myeloid Leukemia as Measured by Patient-Reported Outcomes: Current State and Future Directions11
Telomere Biology Disorder: A Focus on Gastrointestinal and Hepatic Manifestations10
Glucocorticoid Therapy in Acute Lymphoblastic Leukemia: Navigating Short-Term and Long-Term Effects and Optimal Regimen Selection10
Genetic Counseling and Family Screening Recommendations in Patients with Telomere Biology Disorders10
Progress and Challenges in Survivorship After Acute Myeloid Leukemia in Adults10
Contemporary Updates in the Prevention and Treatment of Graft-Versus-Host Disease10
Correction to: Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities9
Blinatumomab in Practice9
Germline CHEK2 and ATM Variants in Myeloid and Other Hematopoietic Malignancies9
Mutant Calreticulin in MPN: Mechanistic Insights and Therapeutic Implications9
BTK Inhibitors in Chronic Lymphocytic Leukemia8
Progress in the Management of Smoldering Multiple Myeloma8
The Bone Marrow Immune Microenvironment in CML: Treatment Responses, Treatment-Free Remission, and Therapeutic Vulnerabilities8
Management of Chronic Myeloid Leukemia in Children and Young Adults7
A Multi-disciplinary Approach to Managing Chronic Myelogenous Leukemia Patients on Oral Anticancer Therapy at a Large Academic Medical Center7
Updates in the Classification of T-cell Lymphomas and Lymphoproliferative Disorders7
NK Cell Therapeutics for Hematologic Malignancies: from Potential to Fruition7
Pelabresib (CPI-0610): An Exciting Novel Drug for the Treatment of Myelofibrosis7
Central Nervous System Relapse in T and NK cell Lymphomas7
0.041513919830322